Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

Now Viewing

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

EP: 13.Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following questions:

• Evobrutinib did not meet its primary endpoint in phase 3 trials. Were you surprised by these results?
• What were the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis?
  • What was seen in the 3-year data?
  • How do payers view the currently available data of tolebrutinib?
• Tolebrutinib is also under investigation in non-relapsing secondary progressive multiple sclerosis. Why is there a need to investigate therapies in this phenotype and what is the phase 3 HERCULES trial design?